^
Association details:
| Biomarker: | BCL2 mutation |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | NX-2127 (IKZF1 degrader, IKZF3 degrader, BTK degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
965 NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton’s Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies
Published date:
11/03/2022
Excerpt:
In this first-in-human, first-in-class study of a BTK degrader, clinical responses and benefit were observed in heavily pretreated (median 6 prior therapies) patients with CLL who have poor prognostic factors, including those with BTK mutations resistant to cBTKi and ncBTKi, BCL2 mutations and those who were previously treated with both BTKi and BCL2 inhibitors.
DOI:
https://doi.org/10.1182/blood-2022-164772
Trial ID:
